2011年7月,美国FDA批准了Bristol-MyersSquibb公司开发的阿巴西普(abatacept)皮下注射剂OrenciaSC,用于治疗成人中至重度活动性类风湿性关节炎,以减少疾病体征和症状,包括诱导主要临床应答、抑制关节结构损害进展和改善机体功能。OrenciaSC可单用、也能与甲氨蝶呤(methotrexate)等化学类疾病修饰性抗风湿病药物共用,但不应与肿瘤坏死因子拮抗剂等生物制剂共用。 In July 2011, the FDA approved OrenciaSC, a subcutaneous injection of abatacept developed by Bristol-Myers Squibb, for the treatment of moderate to severe active rheumatoid arthritis in adults to reduce signs and symptoms of disease, including the induction of predominantly Clinical response, inhibiting the progression of joint damage and improving body function. OrenciaSC can be used alone or in combination with chemical anti-rheumatic drugs such as methotrexate, but not with biological agents such as tumor necrosis factor antagonists.